96 results
8-K
EX-99.1
SIENQ
Sientra Inc
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
for a prompt resolution.
Our primary focus has always been, and continues to be, upholding the highest levels of patient safety. Importantly, the totality … FDA’s compliance requirements, has confirmed the long-term safety and effectiveness of our products. Our peer-reviewed, open-label PACS study
8-K
EX-99.1
SIENQ
Sientra Inc
24 Mar 22
Sientra Receives Regulatory Approval to Market Breast Implants in Canada
8:56pm
, unrivaled ten-year safety data,1 and our industry-leading Platinum20™ warranty.”
Sientra will market its breast implants in Canada through its local … product, safety and service standards to patients and board-certified plastic surgeons.
“After watching its development for close to 20 years
8-K
EX-99.1
SIENQ
Sientra Inc
25 Aug 20
Sientra Receives Regulatory Approval to Market OPUS® Breast
4:05pm
by the PDMA, which reinforces our clinically proven safety profile.”
Jeff continued, “In an era when safety and trust are paramount, Sientra upholds
8-K
EX-99.1
SIENQ
Sientra Inc
9 Oct 15
Other Events
12:00am
by informing them that there has been no indication that these issues would pose a threat to their safety. Furthermore, you should continue to advise … value the relationships we have built with you, and the safety of your patients is of the utmost importance to us. We are providing this update
8-K
EX-99.1
SIENQ
Sientra Inc
11 May 23
Sientra Reports Record First Quarter 2023 Operational Results
4:21pm
further clinical evidence of the compelling safety profile of Sientra’s implants.[2]
Ron Menezes, Sientra’s President and Chief Executive Officer, said, "I … Sientra’s unrivaled safety profile,
[1] Shridharani, S.M., Calobrace, M.B., Dajles, D. and Hamilton, B., “Preliminary Results from Multi-Center Volume
10-K
5o79cz7 ckc
18 Mar 15
Annual report
12:00am
10-Q
4bg87
21 Nov 14
Quarterly report
12:00am